Interferon‐α2b therapy reduces liver fibrosis in chronic non‐A, non‐B hepatitis: A quantitative histological evaluation
Noboru Manabe, Michèle Chevallier, Philippe Chossegros, Xavier Causse, Sylviane Guerret, Christian Trépo, Jean‐Alexis Grimaud – 1 December 1993 – The aim of this study was to evaluate the effect of interferon‐α on liver fibrosis with an established quantitative histochemical method for determining collagen as a marker. 59 patients (31 men, 28 women; 47 ± 14 yr) with chronic non‐A, non‐B hepatitis (92% with hepatitis C virus antibody) received subcutaneous injections of 3 or 1 MU recombinant interferon‐α2b or placebo thrice weekly for 24 wk.